Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sirolimus
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AgelessRx’s PEARL Trial Links Rapamycin Use to Healthspan Improvement
Details : Sirolimus (rapamycin) is an mTOR inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of aging.
Brand Name : Sirolimus
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 10, 2024
Lead Product(s) : Sirolimus
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?